研究单位：[1]TongjiHospital,Wuhan,Hubei,China,430000[2]Chinese Cooperative Group of Liver Cancer (CCGLC)[3]Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province[4]Haplox Biotechnology Co., Ltd.[5]Geneplus-Beijing Co. Ltd.[6]The Second Affiliated Hospital of Fujian Medical University[7]The Second Affiliated Hospital of Fujian Medical University,Quanzhou,Fujian,China,362000
This is a multicenters, ambispective cohort study to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine kinase inhibitor/ anti-VEGF antibody, and anti-PD-1/ PD-L1 antibody for advanced hepatocellular carcinoma which initially unsuitable for the radical therapy, including resection, transplantation, or ablation. Factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
